KTI12: A Protein Involved in Cell Growth, Differentiation and Inflammation

Target Name: KTI12

NCBI ID: G112970

KTI12

KTI12: A Protein Involved in Cell Growth, Differentiation and Inflammation

KTI12 (TOT4) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues. KTI12 has also been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, KTI12 has potential as a drug target or biomarker for a variety of diseases.

One of the key functions of KTI12 is its role in cell growth and differentiation. KTI12 is a transcription factor that regulates the expression of genes involved in cell growth and differentiation. This includes the regulation of cell proliferation, cell survival, and the development of tissues. KTI12 has been shown to play a key role in the development and maintenance of tissues, including the brain, heart, and kidneys.

In addition to its role in cell growth and differentiation, KTI12 is also involved in the regulation of inflammation. KTI12 has been shown to play a role in the regulation of immune responses, including the regulation of T cell development and the regulation of inflammation. This is important because many diseases, including cancer and neurodegenerative diseases, involve inflammation. As a result, KTI12 may be a useful target for drugs that are designed to inhibit inflammation or promote immune responses.

KI12 is also involved in the regulation of cell survival. KTI12 has been shown to play a role in the regulation of cell survival by promoting the production of cell cycle-specific antimitotic drugs (ACMs). ACMs are drugs that inhibit the production of cells that are in the process of dividing, and can be used to treat a variety of diseases, including cancer.

In addition to its role in cell growth, differentiation, and survival, KTI12 is also involved in the regulation of gene expression. KTI12 is a transcription factor that regulates the production of RNA, which is the molecule that carries genetic information from the DNA to the ribosome. This is an important function for the development and maintenance of tissues, and is a key part of the regulation of gene expression.

As a result of its role in the regulation of cell growth, differentiation, and survival, KTI12 has been shown to be involved in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KTI12 has been shown to be involved in the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been shown to play a role in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, KTI12 is a protein that is involved in a variety of functions in the body, including cell growth and differentiation, inflammation, and cell survival. As a result, KTI12 has potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of KTI12 in these processes and to develop treatments that can effectively target it.

Protein Name: KTI12 Chromatin Associated Homolog

The "KTI12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KTI12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets